...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer.
【24h】

Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer.

机译:淋巴结微转移的基因检测:大肠癌术后肝转移患者肝移植的选择标准。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Liver transplantation for nonresectable liver metastases from colorectal cancer was abandoned in 1994 on account of high recurrence rates. The aim of this study was to investigate whether the genetic detection of micrometastases in histologically negative lymph nodes of the primary colon cancer could be applied to select patients for liver transplantation. METHODS: We analyzed 21 patients with colorectal cancer who had undergone liver transplantation between 1983 and 1994 for liver metastases. Eleven patients were histologically lymph node negative at the time of surgery; ten patients with lymph node metastases served as control group. DNA sequencing was used to screen tumor material for p53 and K-ras mutations. Mutant allele-specific amplification (MASA) was then used to search for micrometastases in DNA from regional lymph nodes of the primary colorectal cancer. RESULTS: p53 and K-ras mutations were detected in 12 (57%) and 3 (14%) of 21 patients in the colorectal cancer, respectively. The mutations were confirmed in the corresponding liver metastases. Of 11 patients with histologically negative lymph nodes, nine were eligible for MASA due to presence of p53 or K-ras mutation. MASA revealed six of nine patients to be genetically positive for micrometastases. Three patients were both genetically and histologically negative. These three patients showed a significantly longer overall survival (P = 0.011) of 4, 5, and 20 years, respectively. CONCLUSIONS: We conclude that the genetic detection of micrometastases by MASA could be a powerful prognostic indicator for selecting patients with colorectal liver metastases who could benefit from liver transplantation.
机译:背景:由于高复发率,1994年放弃了用于大肠癌不可切除的肝转移的肝移植。这项研究的目的是调查是否可以在原发性结肠癌的组织学阴性淋巴结中进行微转移的基因检测来选择肝移植患者。方法:我们分析了1983年至1994年之间因肝转移而接受肝移植的21例大肠癌患者。手术时11名患者的组织学淋巴结阴性;十例淋巴结转移患者作为对照组。 DNA测序用于筛选p53和K-ras突变的肿瘤物质。然后使用突变的等位基因特异性扩增(MASA)从原发性大肠癌的区域淋巴结中搜索DNA中的微转移。结果:在21例大肠癌患者中分别检测到p53和K-ras突变,分别为12例(57%)和3例(14%)。在相应的肝转移中证实了该突变。在11例组织学阴性的淋巴结患者中,有9例因存在p53或K-ras突变而符合MASA的资格。 MASA揭示了9例患者中的6例微转移灶基因阳性。三例患者在基因和组织学上均为阴性。这三名患者的总生存期分别为4年,5年和20年,显着更长(P = 0.011)。结论:我们得出结论,MASA的微转移基因检测可能是选择可从肝移植中受益的结直肠肝转移患者的有力预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号